Market Report Source

Overview

Order today and receive a 10% discount off the regular prices listed above

Spectra’s World Market for Gynaecology, 2007-2017 provides a unique assessment of current developments and prospective factors that will shape the global female health market over the next decade. This unrivalled, in-depth market research study commissioned by one of the top three multinational pharmaceutical companies presents a detailed and comprehensive analysis of prescription products used in the diverse areas of infertility, contraception, gynaecological disorders, and menopause.

The market for gynaecology is predicated on hormonal drugs that have recently been subject to controversy based on reports of associated increased risks of cardiovascular disease and cancer. The global market has suffered as a consequence due to cautious prescribing approaches for hormone replacement therapies.

The pipeline however is vast with over 75 hormonal products in clinical development that will offer purer analogues, low-dose formulations, new delivery modes and formats, novel mechanisms of action, and which also confer sophisticated clinical effects over traditional products.

The market for gynaecology is showing signs of a significant upward growth trend over the forecast period to 2017 and the next decade will be exciting, but companies will need to differentiate their products and consider the market forces that may affect product revenue and portfolios.

The World Market for Gynaceology aims to provide an expert analysis of the prescription drug market for female health over the next decade based on current industrial insights, market factors and forces, and trend information. Study objectives include critical assessments of existing products, reviews of products in clinical development, therapy forecasting of product/portfolios to 2017, and market sector analytics by therapeutic category and discrete disorder.

Table of Contents

Contents List 4
List of Tables 12
List of Figures 15
List of Abbreviations 16
Executive Summary 18
Objectives of the Report 21

CHAPTER 1. REPRODUCTION: INFERTILITY ANDOBSTETRIC CONDITIONS 22
1.1 Infertility: Background and Epidemiology 23
1.1.1 Assisted Conception 24
1.2 Pharmacotherapies for Infertility 26
1.2.1 Mechanism of Action of Infertility Pharmacotherapeutics 28
1.3 Product and Market Review for Infertility Pharmacotherapeutics 31
1.3.1 Company 31
1.3.1.1 Key Product and Portfolio Review 32
1.3.1.2 Sales Estimates and Product Market Outlook 32
1.3.2 Company 33
1.3.2.1 Key Product and Portfolio Review 33
1.3.2.2 Pipeline Focus 35
1.3.2.3 Sales Estimates and Product Market Outlook 35
1.3.3 Company 36
1.3.3.1 Key Product and Portfolio Review 36
1.3.3.2 Pipeline Focus 38
1.3.3.3 Sales Estimates and Product Market Outlook 39
1.3.4 Company 40
1.3.4.1 Key Product and Portfolio Review 40
1.3.4.2 Pipeline Focus 42
1.3.4.3 Sales Estimates and Product Market Outlook 43
1.4 Obstetric Conditions 45
1.4.1 Preeclampsia – Background 45
1.4.1.1 Epidemiology 45
1.4.1.2 Pharmacotherapy for Preeclampsia 46
1.4.1.3 Product and Market Overview for Preeclampsia Pharmacotherapy 48
1.4.2 Preterm Labour 49
1.4.2.1 Epidemiology 49
1.4.2.2 Prevention and Treatment 50
1.4.2.3 Pharmacotherapy for Preterm Labour 50
1.4.2.4 Product and Market Overview for Preterm Labour Pharmacotherapy 55
1.4.3 Polycystic Ovary Syndrome 56
1.4.3.1 Aetiology 56
1.4.3.2 Epidemiological Data 56
1.4.3.3 Economic Burden 59
1.4.3.4 Current Treatments – The Evidence 59
1.4.3.5 Product and Market Overview for Polycystic Ovary Syndrome 60

CHAPTER 2. CONTRACEPTION 61
2.1 Hormonal Contraception: Epidemiological Data 62
2.2 Contraception: Inducing Infertility via Ovulation Suppression 63
2.3 Contraceptive Formulations 64
2.3.1 Combined Oestrogen-Progestogen Contraceptives 65
2.3.2 Progestogen-Only Contraceptives 66
2.4 Product Market for Hormonal Contraceptives 69
2.4.1 Company 69
2.4.1.1 Key Product and Portfolio Review 69
2.4.1.2 Sales Estimates and Product Market Outlook 71
2.4.2 Company 72
2.4.2.1 Key Product and Portfolio Review 73
2.4.2.2 Pipeline Focus 76
…Male Contraception 76
2.4.2.3 Sales Estimates and Product Market Outlook 78
2.4.3 Company 79
2.4.3.1 Key Product and Portfolio Review 80
2.4.3.2 Sales Estimates and Product Market Outlook 81
2.4.4 Company 83
2.4.4.1 Key Product and Portfolio Review 83
2.4.4.2 Pipeline Focus 85
2.4.4 3 Sales Estimates and Product Market Outlook 87
2.4.5 Company 88
2.4.5.1 Key Product and Portfolio Review 88
2.4.5.2 Pipeline Focus 89
2.4.5.3 Sales Estimates and Product Market Outlook 90
2.4.6 Company 91
2.4.6.1 Key Product and Portfolio Review 92
2.4.6.2 Pipeline Focus 93
2.4.6.3 Sales Estimates and Product Market Outlook 96
2.5 Intrauterine Devices 98
2.5.1 Safety Concerns 100
2.5.2 Epidemiological Data Related to Intrauterine Devices 100
2.5.3 Types of Intrauterine Devices 101
2.5.3.1 Copper-Bearing Intrauterine Devices 101
2.5.3.2 New Generation Intrauterine Devices 102
2.5.4 Product Market Overview for Intrauterine Devices 103
2.5.4.1 Product Sales Estimates and Market Overview 104

CHAPTER 3. MENSTRUAL AND GYNAECOLOGICAL DISORDERS 106
3.1 Pharmacotherapies for Menstrual and Gynaecological Disorders 107
3.1.1 Mechanism of Action of Treatments for Menstrual and Gynaecological Disorders 107
3.2 Menstrual Disorders: Prevalence, Pathophysiology and Management 109
3.2.1 Pathophysiology of Menstruation 109
3.2.1.1 Anovulation 109
…Aetiology 109
…Treatment 110
3.2.2 Amenorrhoea 112
3.2.2.1 Aetiology 112
3.2.2.2 Epidemiology 112
3.2.2.3 Pharmacotherapies for Amenorrhoea 113
3.2.2.4 Product Market Overview for Amenorrhoea 114
3.2.3 Dysmenorrhoea 115
3.2.3.1 Epidemiology 116
3.2.3.2 Primary Dysmenorrhoea 116
3.2.3.3 Secondary Dysmenorrhoea 116
3.2.3.4 Treatments for Dysmenorrhoea 116
3.2.3.5 Product Market Overview for Dysmenorrhoea 118
3.2.3.6 Future Treatments for Dysmenorrhoea 119
3.2.4 Menorrhagia 119
3.2.4.1 Epidemiology 120
3.2.4.2 Treatments for Menorrhagia 120
3.2.4.3 Product Market Overview for Menorrhagia 122
3.2.4.4 Future Treatment Directions for Menorrhagia 122
3.2.5 Oligomenorrhoea 122
3.2.5.1 Aetiology 122
3.2.5.2 Epidemiology 123
3.2.5.3 Treatments for Oligomenorrhoea 123
3.2.6 Suppression of Cycle 124
3.2.6.1 Contraceptive Treatments for Suppression of Cycle 124
3.2.6.2 Product Market Overview for Cycle Suppression 125
3.2.6 Menstrual Syndromes 125
3.2.6.1 Premenstrual Syndome 125
…Aetiology 126
…Epidemiology 127
…Treatment Options for Premenstrual Syndrome 127
…Drug Therapy for Premenstrual Syndrome 128
…Product Market Overview for Premenstrual Syndrome 129
3.2.6.2 Premenstrual Dysphoric Disorder 130
…Aetiology 130
…Epidemiology 130
…Treatment for Premenstrual Dysphoric Disorder 131
…Product Market Overview for Premenstrual Dysphoric Disorder 132
3.3 Gynaecological Disorders: Prevalence, Pathophysiology and Management 133
3.2.1 Pain-Related Gynaecological Disorders 133
3.2.1.1 Vulvodynia 133
…Epidemiology 133
…Treatment for Vulvodynia 134
…Product Market Overview for Vulvodynia 134
3.2.1.2 Vestibulodynia 134
…Epidemiology 135
…Treatment for Vestibulodynia 135
…Future Research Directions 135
3.2.2 Uterine Disorders 136
3.2.2.1 Endometriosis 136
…Aetiology 137
…Epidemiology 137
…Severity and Symptoms 138
…Treatments for Endometriosis 138
…Hormonal Therapies for Endometriosis 139
…Product Reviews 140
…Product Market Overview for Endometriosis 141
3.2.2.2 Uterine Fibroids 142
…Epidemiology 142
…Symptoms 142
…Treatment Options for Uterine Fibroids 143
…Pharmacotherapy for Uterine Fibroids 144
…Product Market Overview for Uterine Fibroids 144
…Future Research Directions for Uterine Fibroids 145
3.2.2.3 Adenomyosis 145
…Epidemiology 145
…Treatment Options for Adenomyosis 146
…Product Market Overview for Adenomyosis 146
3.2.3 Vaginal Disorders 147
3.2.3.1 Vaginal Atrophy 147
…Symptoms of Vaginal Atrophy 147
…Treatment for Vaginal Atrophy 147
3.2.3.2 Vaginal Dryness 148
…Epidemiology 149
…Symptoms of Vaginal Dryness 149
…Treatment for Vaginal Dryness 149
…Product Market Overview for Vaginal Atrophy and Vaginal Dryness 149
3.2.3.3 Dyspareunia 150
…Epidemiology 150
…Treatment Options for Dyspareunia 150
…Dyspareunia Treatments in Development 150
…Product Market Overview for Dyspareunia 151

CHAPTER 4. THE MENOPAUSE AND MENOPAUSAL SYMPTOMS 152
4.1 Physiological Changes 153
4.2 Epidemiology 154
4.3 General Menopausal Symptoms 154
4.3.1 Systemic Menopausal Symptoms 156
4.3.1.1 Vasomotor Symptoms 156
…Flushes/flashes 157
…Sleep Disturbance 158
…Headache 158
…Palpitations 159
4.3.1.2 Genitourinary Symptoms 159
…Atrophic Vaginitis and Vulvar Atrophy 159
…Atrophic Urethritis 160
4.3.1.3 Other Systemic Conditions and Symptoms 160
…Osteoporosis 160
…Psychological Symptoms and Cognitive Deficits 161
…Cardiovascular Symptoms 162
…Breast Cancer 163
4.4 Treatment for Menopause and Menopausal Symptoms 163
4.4.1 Hormone Therapy 163
4.4.1.1 Routes of Delivery for Hormonal Therapy 164
4.4.1.2 Dosing Regimens for Hormone Therapy 164
4.4.2 Other Pharmaceutical Therapies 165
4.5 Products for Menopause and Menopausal Symptoms 166
4.5.1 Hormone Replacement Therapy 166
4.5.1.1 Oestrogen-Only Hormone Replacement Therapy 166
4.5.1.2 Oestrogen and Progesterone Combined Hormone Replacement Therapy 167
4.5.1.3 Testosterone, and Testosterone plus Oestrogen Combination Hormone 167
Replacement Therapy
4.5.2 Products for Specific Menopausal Symptoms 171
4.6 Product Market Overview for Hormone Replacement Therapies in Menopause 173
4.6.1 Oestrogen-Only and Combined Hormonal Products 173
4.6.1.1 Company 173
4.6.1.2 Company 174
4.6.1.3 Company 175
…Sales Estimates and Product Market Outlook 175
4.6.1.4 Company 176
…Sales Estimates and Product Market Outlook 176
4.6.1.5 Company 177
…Sales Estimates and Product Market Outlook 178
4.6.1.6 Company 179
…Sales Estimates and Product Market Outlook 180
4.6.1.7 Other Monotherapy and Combination Products by Delivery Route 182
4.7 Product Market Overview for Hormonal Contraceptives in Menopause 184
4.8 Hormone Therapy Market in Menopause 185
4.9 Product Market Overview for Nonhormonal Products in Menopause 186
4.9.1 Antidepressants for Vasomotor Symptoms 186

CHAPTER 5. DRUGS IN RESEARCH AND DEVELOPMENT FOR OBSTETRIC AND GYNAECOLOGICAL CONDITIONS 188
5.1 Drugs in Development for Infertility 189
5.1.1 Drugs in Research and Development for Female Infertility 191
5.1.2 Drugs in Development for Male-Factor Infertility 194
5.1.2.1 AstraZeneca – Anastrozole 195
5.1.2.3 Other 195
5.2 Drugs in Development for Obstetric Conditions 197
5.2.1 Preeclampsia 197
5.2.2 Preterm Labour and Labour Induction 200
5.2.2.6 Drugs in Development for Labour Induction 203
5.2.3 Drugs in Development for Polycystic Ovary Syndrome 204
5.3 Products in Development for Contraception 205
5.3.1 Female Hormonal Oral Contraceptives 205
5.3.3 Male Contraception 214
5.3.4 Intrauterine Systems and Devices 217
5.3.4.3 New Research Directions for Intrauterine Devices and Systems 218
5.4 Products in Development for Menstrual and Gynaecological Disorders 220
5.4.1 Menstrual Disorders and Syndromes 220
5.4.1.7 Promising Research Direction in Menstrual Disorders 223
5.4.2 Gynaecological Disorders 224
5.4.2.1 Pain-Related Gynaecological Disorders 224
5.4.2.2 Uterine Disorders 226
…Other Promising Research Directions in Endometriosis 232
5.4.2.3 Vaginal Disorders 232
5.5 Products in Research and Development for Menopause 235
5.5.1 Drugs in Clinical Development for Menopause and Vasomotor Symptoms 235
5.5.2 Drugs in Clinical Development for Postmenopausal Osteoporosis 242
5.5.3 Promising Research Directions in Postmenopausal Osteoporosis 244

CHAPTER 6. THE WORLD GYNAECOLOGY MARKET, 2007-2017 246
6.1 Reproduction: Infertility and Obstetric Conditions 248
6.1.1 The Global Market for Infertility and Obstetric Conditions, 2007-2017 250
6.1.1.1 Market and Competitor Analysis: Infertility 250
… Analysis of Gonadotrophins by Type 251
…Market Outlook for Infertility 255
6.1.1.2 Market Analysis: Obstetric Conditions 255
…Market Outlook for Obstetric Conditions 256
6.1.1.3 Market Analysis: Polycystic Ovary Syndrome 259
…Analysis of Polycystic Ovary Syndrome Support Market by Therapeutic 261
Category: United States
…Market Outlook for Polycystic Ovary Syndrome 262
…Market Summary for Infertility and Obstetric Conditions 262
6.2 Contraception 263
6.2.1 The Global Market for Contraception, 2007-2017 264
6.2.1.1 Product Analysis of Leading Contraceptives 266
6.2.1.2 Market Outlook and Summary for Contraceptives 266
6.3 Menstrual Disorders 272
6.3.1 The Global Market for Menstrual Disorders, 2007-2017 273
6.3.1.1 Product Analysis for Menstrual Disorders 275
…Product Market for Amenorrhoea 276
…Product Market for Dysmenorrhoea 277
…Product Market for Menorrhagia 278
…Product Market for Premenstrual Syndrome 279
…Product Market for Premenstrual Dysphoric Disorder 279
6.3.1.2 Market Outlook for Menstrual Disorders 280
6.4 Gynaecological Disorders 281
6.4.1 The Global Market for Gynaecological Disorders, 2007-2017 283
6.4.1.1 The Market for Pain-Related Gynaecological Disorders, 2007-2017 283
6.4.1.2 The Market for Uterine Disorders, 2007-2017 284
…Product Analysis for Endometriosis 284
…Oral Contraceptives and Hormone Replacement Therapy 286
…Market Outlook for Endometriosis 287
…Product Analysis for Uterine Fibroids 287
…Market Outlook for Uterine Fibroids 288
…Product Analysis for Adenomysosis 288
6.4.1.3 The Market for Vaginal Disorders, 2007-2017 289
…The Market for Vaginal Atrophy and Vaginal Dryness 289
…The Market for Dyspareunia and Vaginal Pain Disorders, 2007-2017 290
…Market Outlook for Vaginal Disorders 291
6.5 Menopause and Vasomotor Symptoms 292
6.5.1 The Global Market for Menopausal Disorders, 2007-2017 294
6.5.1.1 The Market for Hormone Replacement Therapy in Menopause, 2007-2017 297
…Market Outlook for Hormone Replacement Therapy 297
6.5.1.2 The Market for Hormonal Contraceptives in Menopause, 2007-2017 299
6.5.1.3 The Market for Nonhormonal Products in Menopause, 2007-2017 300
6.6 World Market for Gynaecology, 2007-2017 301
6.6.1 Market Analysis 302
6.6.1.1 Market Share by Therapy Area 302
6.6.1.2 Product and Competitor Analysis 302
…Market Leading Gynaecology Products 304
…Market-Leading Companies 305
6.6.1.4 Analysis of Revenue by Geographical Region 306
6.6.1.5 Outlook for World Gynaecology Market, 2007-2107 307

CHAPTER 7. DRUG DEVELOPMENT AND MARKET OPPORTUNITIES 309
7.1 Development and Market Opportunities in Infertility and Obstetric Conditions 311
7.1.1 Drug Development and Market Opportunities in Infertility 312
7.1.1.1 Impact of Infertility: Current Trends and Forecasts 312
7.1.1.2 Current Treatments and Market Opportunities 314
7.1.2 Drug Development and Market Opportunities in Preeclampsia 317
7.1.3 Drug Development and Market Opportunities in Preterm Labour 318
7.1.4 Drug Development and Market Opportunities in Polycystic Ovary Syndome 319
7.2 Development and Market Opportunities in Contraception 321
7.2.1.1 Current Drug Development and Market Opportunities 322
…Nonoral Contraceptives and Market Opportunities 323
…Intrauterine Devices and Market Opportunities 324
7.3 Development and Market Opportunities in Menstrual Disorders 326
7.3.1 Drug Development and Market Opportunities in Menstrual Disorders 327
7.3.1.1 Drug Development and Market Opportunities in Amenorrhoea 327
7.3.1.2 Drug Development and Market Opportunities in Dysmenorrhoea 327
7.3.1.3 Drug Development and Market Opportunities in Menorrhagia 328
7.3.1.4 Drug Development and Market Opportunities in Premenstrual Syndrome and Premenstrual Dysphoric Disorder 328
7.3.1.5 Drug Development and Market Opportunities in Other Menstrual Conditions 329
7.4 Development and Market Opportunities in Gynaecological Disorders 330
7.4.1 Development and Market Opportunities in Pain-Related Gynaecological Disorders 331
7.4.2 Development and Market Opportunities in Uterine Disorders 331
7.4.2.1 Endometriosis 331
7.4.2.2 Uterine Fibroids 332
7.4.3 Development and Market Opportunities in Vaginal Disorders 333
7.5 Development and Market Opportunities in Menopause/Vasomotor Symptoms 334
7.5.1 Development and Market Opportunities in Hormone Replacement Therapy 335
7.5.2 Development and Market Opportunities in Vasomotor Symptoms 336
7.5.2.2 Other Development and Market Opportunities 338

CHAPTER 8. KEY POINTS:CONCLUSIONS AND CONSIDERATIONS 339
8.1 Infertility and Obstetrics 340
8.2 Contraception 341
8.3 Menstrual and Gynaecological Disorders 342
8.4 Menopause and Vasomotor Symptoms 343

LIST OF TABLES
Table 1.1 Biological Causes of Infertility 24
Table 1.2 Assisted Conception Techniques 27
Table 1.3 Pharmacotherapies for Infertility, 2007 30
Table 1.4 [Company] Hormonal Infertility Product Portfolio, 2007 31
Table 1.5 Estimated Global Sales (US$) and Annual Growth (%) of [Company] Hormonal Infertility Products, 2005-2017 32
Table 1.6 [Company] Infertility Product Portfolio, 2007 34
Table 1.7 Estimated Global Sales (US$) and Annual Growth (%) of [Company] Infertility Products, 2005-2017 35
Table 1.8 [Company] Hormonal Infertility Product Portfolio, 2007 37
Table 1.9 Estimated Global Sales (US$) and Annual Growth (%) of [Company] Hormonal Infertility Products, 2005-2017 39
Table 1.10 [Company] Hormonal Infertility Product Portfolio, 2007 41
Table 1.11 Estimated Global Sales (US$) and Annual Growth (%) of [Company] Hormonal Infertility Products, 2005-2017 43
Table 1.12 Selected Antihypertensives Used in the Treatment of Preeclampsia, 2007 47
Table 1.13 Evidence-Based Treatments for Preterm Labour 52
Table 1.14 Drugs Indicated for Preterm Labour, Maintenance of Labour, and Labour Induction 53
Table 1.15 Selected Drugs used for Treating the Sequelae of Preterm Labour 54
Table 1.16 Potential Drugs used for Treating the Symptoms of Polycystic Ovary Syndrome 58
Table 1.17 Annual Estimates of Treatment Costs for Polycystic Ovary Syndrome in the United States 59
Table 2.1 Global Prevalence Rates of Oral Contraceptive Use 63
Table 2.2 Popular Combined Oral Contraceptives, 2007 66
Table 2.3 Popular Contraceptives Segmented by Formulation and Delivery Route, 2007 68
Table 2.4 [Company] Hormonal Contraceptive Product Portfolio, 2007 69
Table 2.5 Estimated Sales (US$) and Annual Growth (%) of [Company] Hormonal Contraceptive Portfolio, 2005-2017 71
Table 2.6 [Company] Hormonal Contraceptive Product Portfolio, 2007 73
Table 2.7 Estimated Sales (US$) and Annual Growth (%) of [Company] Hormonal Contraceptive Portfolio, 2005-2017 78
Table 2.8 [Company] Hormonal Contraceptive Product Portfolio, 2007 79
Table 2.9 Estimated Sales (US$) and Annual Growth (%) of [Company] Hormonal Contraceptive Portfolio, 2005-2017 82
Table 2.10 [Company] Hormonal Contraceptive Product Portfolio, 2007 83
Table 2.11 [Company] Pipeline Contraceptive Candidates, 2007 86
Table 2.12 Estimated Sales (US$) and Annual Growth (%) of [Company] Hormonal Contraceptive Portfolio, 2005-2017 87
Table 2.13 [Company] Hormonal Contraceptive Product Portfolio, 2007 88
Table 2.14 Estimated Sales (US$) and Annual Growth (%) of [Company] Hormonal Contraceptive Portfolio, 2005-2017 90
Table 2.15 [Company] Proprietary and Generic Contraceptive Product Portfolio, 2007 95
Table 2.16 Estimated Sales (US$) and Annual Growth (%) of [Company] Portfolio, 2005-2017 96
Table 2.17 Popular Intrauterine Devices and Systems, 2007 99
Table 2.18 Estimated Global Sales (US$) and Annual Growth (%) of Intrauterine Devices, 2005-2017 104
Table 3.1 Causes of Anovulation 110
Table 3.2 Pharmacotherapies for Anovulation 111
Table 3.3 Medical Conditions Associated Causally with Amenorrhoea 113
Table 3.4 Estimated Global Sales (US$) of Leading Products for Amenorrhoea, 2006 115
Table 3.5 Common and Associated Symptoms of Dysmenorrhoea 115
Table 3.6 Treatment Options for Dysmenorrhoea 117
Table 3.7 Estimated Global Sales (US$) of Leading Products for Dysmenorrhoea, 2006 118
Table 3.8 Treatment Options for Menorrhagia and Heavy Blood Flow 121
Table 3.9 Common Symptoms of Premenstrual Syndrome 126
Table 3.10 Common Treatment Options for Premenstrual Syndrome 128
Table 3.11 Estimated Global Sales (US$) of Leading Products for Premenstrual Syndrome, 2006 130
Table 3.12 Commonly Prescribed Tricyclic Antidepressants for the Treatment of Vestibulodynia 136
Table 3.13 Treatments for Endometriosis in Order of Effectiveness 139
Table 3.14 Medical and Surgical Treatment Options for Uterine Fibroids 143
Table 3.15 Drugs Used in the Treatment of Vaginal Atrophy 148
Table 4.1 Systemic Menopausal Symptoms 156
Table 4.2 Common Signs and Symptoms of Atrophic Vaginitis and Vulvar Atrophy During the Menopausal Transition 160
Table 4.3 Hormone Therapy Regimens 164
Table 4.4 Hormone Replacement Therapies for the Menopause, 2007 169
Table 4.5 Treatment Options for Menopausal Symptoms 171
Table 4.6 Estimated Sales (US$) and Annual Growth (%) of [Company] Hormonal Replacement Therapy Portfolio, 2006-2017 175
Table 4.7 Estimated Sales (US$) and Annual Growth (%) of [Company] Hormonal Replacement Therapy Portfolio, 2006-2017 177
Table 4.8 Estimated Sales (US$) and Annual Growth (%) of [Company] Hormonal Replacement Therapy Portfolio, 2006-2017 178
Table 4.9 Global Sales (US$) and Annual Growth (%) of [Company] Premarin Franchise, 2002-2006 181
Table 4.10 Estimated Sales (US$) and Annual Growth (%) of [Company] Hormonal Replacement Therapy Portfolio, 2006-2017 182
Table 4.11 Selected Hormone Replacement Therapy Products by Delivery Route 183
Table 4.12 Estimated Global Sales (US$) of Leading [Drugs] Used in the Treatment of Menopausal Symptoms and Syndromes 187
Table 5.1 Drugs in Research and Development for Female and Male Infertility, 2007 190
Table 5.2 Drugs in Research and Development for Preeclampsia, 2007 197
Table 5.3 Drugs in Clinical Development for Preterm Labour and Labour Induction, 2007 200
Table 5.4 Drugs in Clinical Development for Polycystic Ovary Syndrome, 2007 204
Table 5.5 Female Oral Contraceptives in Clinical Development, 2007 206
Table 5.6 [Company] Pipeline Contraceptive Products, 2007 207
Table 5.7 Nonoral Female Contraceptives in Clinical Development, 2007 212
Table 5.8 Male Contraceptives in Clinical Development, 2007 214
Table 5.9 Intrauterine Systems and Devices in Clinical Development, 2007 217
Table 5.10 Products in Clinical Development for Menstrual Disorders and Syndromes, 2007 222
Table 5.11 Products in Clinical Development for Pain-Related Gynaecological Disorders, 2007 225
Table 5.12 Products in Clinical Development for Uterine Disorders, 2007 228
Table 5.13 Products in Clinical Development for Vaginal Disorders, 2007 233
Table 5.14 Products in Clinical Development for Menopause and Related Vasomotor Symptoms, 2007 237
Table 6.1 Estimated Global Sales (US$) and Forecasts of Leading Drugs for Infertility and Obstetric Conditions, 2004-2017 249
Table 6.2 Estimated Global Sales (US$) and Forecasts of Leading Infertility Portfolios, 2004-2017 251
Table 6.3 Estimated Global Sales (US$) and Forecasts of Gonadotrophins by Company and Type, 2005-2017 254
Table 6.4 Estimated Global Sales (US$) and Forecasts of Leading Drugs for Obstetric Conditions, 2004-2017 256
Table 6.5 Estimated Global Sales (US$) and Forecasts of the Polycystic Ovary Syndrome Support Market by Therapeutic Category, 2004-2017 260
Table 6.6 Estimated Global Sales (US$) and Forecasts of Leading Contraceptive Portfolios, 2004-2017 264
Table 6.7 Estimated Global Sales (US$) and Forecasts of Products for Menstrual Disorders, 2004-2017 273
Table 6.8 Sales Estimates for Leading Products Used to Treat Amenorrhoea, 2007-2017 276
Table 6.9 Sales Estimates for Leading Products Used to Treat Dysmenorrhoea, 2007-2017 277
Table 6.10 Sales Estimates for Leading Products Used to Treat Menorrhagia, 2007-2017 278
Table 6.11 Sales Estimates for Leading Products Used to Treat Premenstrual Syndrome, 2007-2017 279
Table 6.12 Sales Estimates for Leading Products Used to Treat Premenstrual Dysphoric Disorder, 2007-2017 280
Table 6.13 Estimated Global Sales (US$) and Forecasts of Products for Gynaecological Disorders, 2004-2017 282
Table 6.14 Gonadotrophin-Release Inhibitors Available for the Management of Endometriosis 285
Table 6.15 Sales Estimates for Gonadotrophin-Release Inhibitors Used in Endometriosis, 2007-2017 285
Table 6.16 Sales Estimates for Endometriosis by Product Type, 2007-2017 286
Table 6.17 Sales Estimates for Uterine Fibroids by Product Type, 2007-2017 288
Table 6.18 Sales Estimates for Products to Treat Vaginal Atrophy/Dryness, 2007-2017 290
Table 6.19 Sales Estimates for Dyspareunia and Vaginal/Vulvar Pain Disorders, 2007-2017 291
Table 6.20 Estimated Global Sales (US$) and Forecasts of Products for Menopause and Vasomotor Symptoms, 2004-2017 293
Table 6.21 World Gynaecology Market – Estimated Global Sales (US$) and Forecasts, 2004-2017 301
Table 6.22 Estimated Global Sales (US$) and Forecasts of Leading Gynaecology Products, 2005-2017 305
Table 7.1 Estimated Female and Male Primary Infertility Rates in the United States and Europe, 1982-2017 315

LIST OF FIGURES
Figure 1.1 Lifestyle Factors Affecting Fertility 25
Figure 2.1 Estimated Worldwide use (%) of Intrauterine Devices among Married Women Aged 15-49 Years, 2005 101
Figure 6.1 Estimated Global Sales of Infertility Products by Company, 2007 & 2017 252
Figure 6.2 Estimated Global Market Share of Infertility Products by Company, 2007 & 2017 253
Figure 6.3 Estimated Global Sales of Drugs to Treat Preeclampsia and Preterm Labour, 2007 & 2017 257
Figure 6.4 Estimated Global Market Share of Products to Treat Obstetric Conditions, 2007 & 2017 258
Figure 6.5 Estimated Global Sales of Support Products to Treat Polycystic Ovary Syndrome, 2007-2017 261
Figure 6.6 Global Sales of Leading Hormonal Contraceptives by Company, 2004-2017 265
Figure 6.7 Estimated Global Market Share of Leading Contraceptives, 2007 & 2017 267
Figure 6.8 Estimated Global Market Share for Menstrual Disorders, 2007 & 2017 274
Figure 6.9 Estimated Market Share Distribution of Menstrual Disorders , 2004-2017 275
Figure 6.10 Estimated Market Share of Drugs to Treat Endometriosis by Type, 2007 287
Figure 6.11 Projected Growth Trends for Menopausal Products by Sales, 2004-2017 295
Figure 6.12 Estimated Market Share for Menopausal Product Categories, 2007 & 2017 296
Figure 6.13 Product Sales Distribution for Leading Menopause Products, 2004-2017 298
Figure 6.14 Estimated Market Share for Gynaecology Products by Therapy Area, 2007 302
Figure 6.15 Estimated Market Share for Gynaecology Products by Therapy Area, 2017 303
Figure 6.16 Market Growth by Revenues for Therapy Areas in Gynaecology, 2004-2017 304
Figure 6.17 Market-Leading Companies in Gynaecology by Revenues, 2007 306
Figure 6.18 Estimated Share of the Gynaecology Market by Geographical Region, 2007 307